Meeting
2023 ASCO Annual Meeting
Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable high grade glioma patients: OLA-TMZ-RTE-01.
Authors
Dinu Stefan
Centre François Baclesse, Radiation Oncology Department, Caen, France
Dinu Stefan , Justine Lequesne , Sunyach Marie , Delphine Larrieu-Ciron , Charlotte Bronnimann , Julien Geffrelot , Jeanne Riverain , Pierre-Emmanuel Brachet , Joelle Lacroix , Fernand Missohou , Maxime Faisant , Evelyne Emery , Elisabeth Moyal , Bérénice Legrand , Gwenaelle Boudier , Marie Castera , Jean-Michel Grellard , Paul Lesueur , Benedicte Clarisse , Loic Feuvret
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Primary CNS Tumors–Glioma
Clinical Trial Registration Number
NCT03212742
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 2046)
DOI
10.1200/JCO.2023.41.16_suppl.2046
Abstract #
2046
Poster Bd #
403
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Phase I clinical trials evaluating olaparib in combination with radiotherapy (RT) and/or temozolomide (TMZ) in glioblastoma patients: Results of OPARATIC and PARADIGM phase I and early results of PARADIGM-2.
First Author: Anthony J. Chalmers
Poster
2013 ASCO Annual Meeting
Phase I adult brain tumor consortium (ABTC) trial of ABT-888 (veliparib), temozolomide (TMZ), and radiotherapy (RT) for newly diagnosed glioblastoma multiforme (GBM) including pharmacokinetic (PK) data.
First Author: Lawrence Kleinberg
Poster
2020 ASCO Virtual Scientific Program
Radioparp: A phase I of olaparib with radiation therapy (RT) in patients with inflammatory, locoregionally advanced or metastatic triple-negative breast cancer (TNBC) or patient with operated TNBC with residual disease—Preliminary results.
First Author: Youlia M. Kirova
Poster
2019 ASCO Annual Meeting
A TITE-CRM phase I/II study of disulfiram and copper with concurrent radiation therapy and temozolomide for newly diagnosed glioblastoma.
First Author: Jiayi Huang